HKG: 2162

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years and…

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis

CompanyDrug

Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study

CompanyDrug

InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study

CompanyDeals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

CompanyDrug

Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors

CompanyDrug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Show More